Skip to main content

Table 1 Baseline data of BC patients receiving NAC

From: A nomogram based on platelet-to-lymphocyte ratio for predicting pathological complete response of breast cancer after neoadjuvant chemotherapy

Factors

Non-pCR (N = 55)

pCR (N = 57)

Total

X2

P

Age (Years)

<44.5

9

16

25

2.212

0.137

≥ 44.5

46

41

87

Menarche age (Years)

<13.5

27

35

62

1.717

0.190

≥ 13.5

28

22

50

Menstrual states

No

13

15

28

0.107

0.743

Yes

42

42

84

Menopausal age (Years)

<51.5

37

30

67

3.614

0.057

≥ 51.5

5

12

17

Primiparous age (Years)

<22.5

24

32

56

1.751

0.186

≥ 22.5

31

25

56

Number of births

<3

43

50

93

1.808

0.179

≥ 3

12

7

19

cT

1/2

45

47

92

0.008

0.930

3/4

10

10

20

cN

0/1

37

35

72

0.517

0.472

2/3

14

18

32

cM

0

50

52

102

 

1.000a

1

2

3

5

Axillary lymph nodes

Negative

11

6

17

1.951

0.162

Posotive

14

51

65

Pathological type

IDC

55

53

108

 

0.119a

Other

0

4

4

Grade

1/2

47

34

81

4.764

0.029

3

7

15

22

ER

Negative

16

28

44

4.404

0.036

Positive

30

29

59

PR

Negative

19

27

46

1.696

0.193

Positive

35

30

65

HER-2

Negative

13

8

21

1.822

0.177

Positive

41

49

90

Ki-67

<42.50

36

28

64

3.049

0.081

≥ 42.50

19

29

48

Molecular classification

Luminal A

0

1

1

 

0.063a

Luminal B(HER-2−)

10

3

13

Luminal B(HER-2+)

28

25

53

HER-2+

13

24

37

Triple negative

3

4

7

Therapy cycle

<7

28

18

46

4.321

0.038

≥ 7

27

39

66

CEA (ng/mL)

<2.93

42

35

77

3.682

0.055

≥ 2.93

11

21

32

CA153 (U/mL)

<19.14

35

31

66

1.300

0.254

≥ 19.14

18

35

53

Hb (g/L)

<135.50

30

35

65

0.541

0.462

≥ 135.50

25

22

47

WBC (×10^9/L)

<6.13

13

23

36

4.475

0.034

≥ 6.13

43

34

77

PLT (×10^9/L)

<247.50

27

17

44

4.356

0.037

≥ 247.50

28

40

68

LYM (×10^9/L)

<1.64

35

13

48

0.352

<0.001

≥ 1.64

20

44

64

NEU (×10^9/L)

<4.70

25

33

58

1.735

0.188

≥ 4.70

30

24

54

Monocyte (×10^9/L)

<0.44

38

47

85

2.733

0.098

≥ 0.44

17

10

27

ALB (g/L)

<52.15

5

2

7

 

0.434a

≥ 52.15

41

43

84

NLR

<2.02

6

28

34

19.334

<0.001

≥ 2.02

49

29

78

PLR

<161.50

18

42

60

18.878

<0.001

≥ 161.50

37

15

52

LMR

<6.39

45

29

74

11.954

0.001

≥ 6.39

10

28

38

SII

<598.50

13

32

45

12.304

<0.001

≥ 598.50

42

25

67

  1. a Fisher exact probability method. BC: Breast cancer; NAC: Neoadjuvant chemotherapy; pCR: Pathological complete response; IDC: Invasive ductal carcinoma; ER: Estrogen receptor; PR: Progesterone receptor; HER-2: Human epidermal growth factor receptor-2; CEA: Carcinoembryonic antigen; CA153: Carbohydrate antigen 153: WBC: White blood cell; Hb: Hemoglobin; PLT: Platelet; LYM: Lymphocyte; ALB: Albumin; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; LMR: Lymphocyte-to-monocyte ratio; SII: Systemic immune inflammation index.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us